A large body of data indicates that activation of NF-κB contributes to the pathophysiology of ischemic stroke and, therefore, inhibition of NF-κB has been suggested as a potential therapeutic strategy against post-stroke brain inflammation [32,33,34]. This evidence concerns the gene NFKB1 and ischemic stroke.